Sun Pharma receives USFDA nod for Venlafaxine tablets

MUMBAI: Sun Pharmaceuticals Industries Ltd has received US Food and Drug Administration’s approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Venlafaxine Hydrochloride Extended Release tablets.

These generic extended release Venlafaxine tablets are therapeutically equivalent to Osmotica’s Venlafaxine Hydrochloride Extended Release tablets and include three strengths: 37.5 mg (base), 75 mg (base), 150 mg (base).

Venlafaxine Hydrochloride extended release tablets are indicated for the management of major depressive disorder, generalized anxiety disorder, panic disorder.

The company has received 180-day marketing exclusivity. The product will reach the market shortly.

On NSE, the company's shares were up 1.51 per cent at Rs 1,795.80. The stock touched a high of Rs 1,802.80 versus a low of Rs 1,760.15.